ICONAN 2017 conference will gather high-profile Nanomedicine and Nanobiotechnology experts to deliver plenary speeches:
Prof. Víctor F. Puntes
ICREA Research Prof Víctor F. Puntes’ work spans the full breadth of nanoparticle research: synthesis, conjugation and characterisation of inorganic nanoparticles; nanotoxicology and nanosafety; and myriad applications for sectors including medicine and the environment.
Prof Puntes completed his undergraduate studies in Chemical Engineering and Materials Science at the Université Louis Pasteur Strasbourg (France) and at the Universitat Autònoma de Barcelona (UAB). In 1998, he earned his PhD in Physics from the Universitat de Barcelona (UB), working with Prof Xavier Batlle and Prof Amilcar Labarta on Giant Magnetoresistance in granular alloys. He then spent more than 3 years at the University of California, Berkeley, and the Lawrence Berkeley National Laboratory (LBNL), in the groups of Prof Paul Alivisatos and Prof Kannan Krishnan, working on the synthesis and control of nanostructures. In 2003 he returned to Catalonia with a Ramón y Cajal research position at the University of Barcelona, and in 2005 obtained an ICREA Professorship at ICN to create the Inorganic Nanoparticles Group, which he presently heads.
By the end of 2013, Prof Puntes held 110 peer-reviewed publications and over 6,000 total citations. He is also well-known for his work in science communication for the general public, his industrial and commercial efforts, and for his endeavours linking science and art.
By the end of 2014, Prof Puntes held 110 peer-reviewed publications and over 7,000 total citations.
Talk title: The Nanopharmacokinetic Gap
Prof. Alexander Seifalian
Nanotechnology and Regenerative Medicine Commercialisation centre, UK
Alexander Seifalian, Professor of Nanotechnology and Regenerative Medicine and Director of Nanotechnology and Regenerative Medicine Company has worked at Royal Free Hospital and University College London over 25 years, published over 647 peer-reviewed research papers, edited 2 books and contributed to 39 book chapter, and 14 UK and International patents. He is currently director of NanoRegMed Ltd, working in commercialisation of his research.
During his career he has led and managed many large projects with multidisciplinary teams with very successful outcomes in terms of commercialisation and translation to patients including 1) The development and commercialisation of a bypass graft for vascular access for haemodialysis; 2) The development of bioreactors with fluid dynamic systems; 3) Non-invasive techniques to monitor viscoelastic properties of cardiovascular system and many others.
He was awarded the top prize in the field for the development of nanomaterials and technologies for cardiovascular implants in 2007 by Medical Future Innovation, and in 2009 received a Business Innovation Award from UK Trade & Investment (UKTI) in the Life Sciences and Healthcare category. European Life Science Awards. Winner of most innovative new product 2012 “Synthetic Trachea”. Hamburg, Germany, 29 may 2012. He also was awarded Nanosmat Prize in August 2013 in Spain for his achievements and contributions to Nanoscience and nanotechnology. In 2016 in Brussels he received the Heals distinguish research award in recognition for his outstanding work in regenerative medicine from Heals Healthy Life Extension Society.
He developed world first synthetic trachea, lacrimal drainage conduit, and vascular bypass graft using nanocomposite materials and bioactive molecules and stem cells technology. He has created a huge amount of media interest for his translational research work to first in man, including; world first synthetic trachea, bypass graft, lacrimal duct, and other surgical implants.
Talk title: Nanotechnology based materials to repair and rebuild human organs
Dr. Hak Soo Choi
Harvard Medical School, USA
Dr. Choi is an Associate Professor of Radiology at Harvard Medical School, and faculty of Dana Farber/Harvard Cancer Center. He is Director of Bioengineering and Nanomedicine Program of the Gordon Center for Medical Imaging, Massachusetts General Hospital. Dr. Choi has published over 100 papers in the field of biomaterials and bioimaging, and his laboratory focuses on the development of novel targeted agents to solve important problems in oncology and clinical medicine, with an emphasis on in vivoimaging and tissue-specific contrast agent development. Of particular interest is targeted fluorophores, which can be used for image-guided surgery by specifically visualizing target tissue with high optical properties and by avoiding nonspecific uptake in normal background tissues.
Talk title: Structure-Inherent Targeting for Bioimaging and Nanomedicine
Prof. Stephan Barcikowski
University of Duisburg-Essen, Germany
Stephan Barcikowski studied chemistry in Braunschweig and Hannover, and made his PhD in Mechanical Engineering (Materials). At the Laser Zentrum Hannover, Barcikowski built up the Nanomaterials group, and later led the institute’s Materials Processing Department. In 2010, he co-founded the company Particular GmbH (www.particular.eu ). Since 2011, he chairs the Institute of Technical Chemistry I at the University of Duisburg-Essen and he is scientific director of the Center for Nanointegration Duisburg-Essen CENIDE (https://www.uni-due.de/
Talk title: Ligand-free metal nanoparticle colloids: benefits in standardized toxicity assays and functional bioconjugates
Prof. Duncan Craig
UCL School of Pharmacy, UK
Professor Duncan Craig graduated with a BPharm (Hons) from the University of Bath in 1984 and, following pre-registration training at Upjohn Ltd and St Thomas’ Hospital, went on to study for a PhD at the School of Pharmacy, University of London, on the topic of polymeric drug delivery systems. He subsequently joined the staff and rose to the position of Reader in 1999 but left to take up a chair at the Queen’s University Belfast, where he stayed for four years before moving to the University of East Anglia to set up the new School of Pharmacy in 2003. The School went on to achieve top ranking in the national student survey for five years in a row and was consistently ranked within the top 3 UK pharmacy schools in the major league tables. He stepped down as Head of School in 2011 to work for the Vice-Chancellor’s Office as Director of Internationalisation, charged with shaping the university’s policy on international relations and collaborations. In 2013 he returned to the School of Pharmacy, now part of UCL, to assume the position of Director of the newly merged School. Professor Craig has won numerous prizes including the GlaxoSmithKline International Achievement Award, the Controlled Release Society Young Investigator Award and the British Pharmaceutical Conference Science Award.
Talk title: Nano-engineered drug delivery systems; from oral administration to compartmentalised particles
Prof. Rachel Auzely
Centre de Recherches sur les Macromolécules Végétales – CNRS, France
Rachel Auzély-Velty, 45, graduated from the chemical engineering school of Rennes (Ecole Nationale Supérieure de Chimie de Rennes) and obtained a Master in Chemistry of the University of Rennes (Rennes, France) in 1994. After obtaining her PhD in organic chemistry from the same university in 1997, she undertook post-doctoral research at the Commissariat à l’Energie Atomique (CEA, Saclay) in 1998-1999 in the field of cyclodextrin chemistry with Dr. B. Perly. After being a CNRS researcher in the CNRS research laboratory, CERMAV (Grenoble) from 1999 to 2005, she became full Professor at the Grenoble Alpes University (Grenoble). She is group leader of the “Structure and Modification of Polysaccharides” group in CERMAV. She was a Junior member of the Institut Universitaire de France (IUF) (2009-14). Her research interests lie in the fields of chemical modification and characterization of water-soluble polysaccharides (in particular, hyaluronic acid and chitosan), and of biomaterials. Potential target applications include controlled and targeted drug delivery, surface modification, tissue engineering and cell biology. Prof. R. Auzély is co-author of over 85 publications, 4 book chapters and is co-inventor of 10 patent applications. In recognition of her work, she was named “Knight of the National Order of Merit” by the French minister for Research (2014).
Talk title: Stimuli-responsive polysaccharide nanogels for the targeted treatment of cancer
Dr. Julien Nicolas
Galien Paris-Sud Institute (UMR CNRS 8612), France
Julien Nicolas completed his Ph.D. in 2005 under the supervision of Prof. Bernadette Charleux at the University Pierre and Marie Curie in Paris (France), where he studied nitroxide-mediated polymerization. He then joined the group of Prof. David M. Haddleton at the University of Warwick (U.K.), as a postdoctoral researcher (Marie Curie Intra-European Fellowship) in the field of polymer–protein bioconjugates. In 2007, he obtained a CNRS researcher position at Institut Galien Paris-Sud (Univ. Paris-Sud) in Châtenay-Malabry (France) and was promoted to CNRS research director in 2016. His current research activities lie in advanced macromolecular synthesis and in the design of innovative polymer-based nanomedicines. He is (co)author of more than 80 peer review articles in international journals, 5 patents, and 13 book chapters. Since October 2016, he serves as Associate Editor for Chemistry of Materials (ACS).
Talk title: New strategies for polymer-based nanomedicines
Prof. Damjana Drobne
University of Ljubljana, Slovenia
Damjana Drobne is a Professor of Zoology and Professor of Toxicology from the University of Ljubljana with over twenty-five years of research experiences. She is the founder and principal investigator of a research group for nanobiology and nanotoxicology (http://www.bionanoteam.com/). Her research group has developed a series of methods for testing effects of metals or nanomaterials on cells, tissue and organisms as well as how to follow the internal distribution of metals once entering the organisms. She has an outstanding expertise in biological sample preparation for focused ion beam/scanning electron microscopy and spectroscopy. During the course of her entire scientific research, the enzyme AChE has become a central molecule of interest due to its ubiquitous functions and presence in various tissues and organisms as well as due to its wide use as a biomarker of (neuro)toxicity. More recently the true challenge in the AChE research is devoted to its non-neuronal functions. Up to now, she has published together with co-authors more than 100 original scientific publications and many book chapters. Her group is a partner in two large scales 7.OP EU projects (NanoMile, NanoValid), a Horizon 2020 project (NanoFase) and a partner in Horizont 2020 MSCA-ITN-2015 project (Pandora). At a national level, her group is a partner in two national centers of excellence (CO NAMASTE and CO NanoCentre). Since 2001, she is continuously coordinating national research projects. Recently she become an advisor to Slovenian Innovation Hub- European Economic Interest Grouping ( http://www.sis-egiz.eu/) as an expert responsible for nanosafety. Prof. Dr. Damjana Drobne has supervised or co-supervised about 20 PhD students. She is lecturing at undergraduate as well as postgraduate study programs at University of Ljubljana in different courses on zoology, toxicology, nanobiology and nanotoxicology.
Talk topics: Nanosafety and industry: needs, expectations and challenges
Prof. María José Alonso
University of Santiago de Compostela, Spain
María José Alonso is full professor of Biopharmaceutics and Pharmaceutical Technology at the University of Santiago de Compostela (USC). Her lab has pioneered numerous discoveries in the field of Nanopharmaceutical Technology and nanomedicine. She has coordinated several research consortia financed by the WHO, the Gates Foundation and the European Commission. Currently, she is involved in 5 EU Projects and she is coordinating the TRANS-INT EU consortium. She is the author of over 230 scientific contributions with more than 11,500 cites (H factor 65) and the inventor of 18 patent families. Because of the quality of her papers she has been among the TOP TEN in Pharmacology (Times Higher Education international ranking). She is currently the Secretary of the Controlled Release Society. She also serves on the editorial board of the 10 journals. In 2006-10, she was the Vice-rector of Research and Innovation of the USC. She has advised the Ministry of Sciences and Innovation in the elaboration of the Low of Sciences, technology and Innovation, 2011 and, she has been part of the advisory council of the Ministry of Health in Spain. She is also a member of three Academies in Spain and the US National Academy of Medicine.
Talk title coming soon
Prof. Philippe Barthélémy
Bordeaux Segalen University, France
Professor Philippe Barthélémy is the team leader of the ChemBioPharm team of the INSERM unit ARNA and is an expert in hybrid, bioinspired molecules, including nucleoside lipids, glycosylated nucleoside lipids, amino-acid nucleoside lipids and lipid oligonucleotide conjugates. His contribution to this field has been recognized by several prizes including the “Ministère Oseo 2011 Emergence », «Tremplin Entreprise/ESSEC 2011 », Future of innovation (InnovaDay, 2010), « Young observer of IUPAC » Pékin, Chine, (2005) and Ottawa, Canada, (2003). P. Barthélémy was a postdoctoral fellow at Emory University (Lavoisier Grant and Emory Fellowship). P. Barthélémy worked also as a Visiting Associate Professor at Duke University in 2001. In 2005 he was appointed as full Professor at the University of Bordeaux Segalen. Philippe Barthélémy was Vice President of the University of Bordeaux Segalen in 2012.. He is the cofounder of the startup inanov created in 2014. Philippe Barthélémy published >100 publications in peer-reviewed journals > 15 patents, >100 communications and conférences.
Talk title coming soon
Prof. María Vallet Regí
Complutense University of Madrid, Spain
María Vallet Regí is Full Professor of Inorganic Chemistry at UCM, leader of the Smart Biomaterials Group, Head of Research at CIBER-BBN and at Hospital 12 de Octubre Research Institute (i+12). Recipient of an ERC Advanced Grant: Polyvalent mesoporous nanosystem for bone diseases.
Full Member of the Spanish Royal Academies of Pharmacy (RANF) and Engineering (RAI). Fellow of Biomaterials Science and Engineering, appointed by the International Union of Societies, Biomaterials Science & Engineering (FBSE). Member, College of Fellows of the American Institute for Medical and Biological Engineering (AIMBE)
French Spanish Award of Societé Française de Chimie in 2000, RSEQ 2008 Award in Inorganic Chemistry, National Research Award 2008, FEIQUE Research Award 2011, RSEQ Gold Medal awarded in 2011. Doctor Honoris Causa by the Basque Country and Jaume I Universities. IUPAC 2013 Distinguished Women in Chemistry/Chemical Engineering and Miguel Catalán Research Award 2013. Lilly Distinguished Career Award in Chemistry 2016.
Acknowledged as pioneer in the field of mesoporous ceramic materials with biomedical applications. Her research revealed, for the first time, the potential biomedical applications of these materials, particularly in the fields of bone regeneration and controlled drug release systems (Chem. Mater. 13,308-311, 2001; 1469 citations). Her novel line of work lead to the development of a new field of research (more than 5,500 published papers so far).
She is also among the top 50 European scientists in the field of Materials Science, and one of the top 5 European scientists working in Biomedical Materials. Her multifaceted research work is reflected in more than 28,000 citations in the fields of materials Science, Chemistry, Pharmacy and Medicine.
Talk title: Response-triggering stimuli in drug release
Dr. Kai Licha
Freie Universität Berlin, Institute of Chemistry and Biochemistry, Berlin, Germany
Kai Licha is currently faculty member at the Freie Universität Berlin and leading a research group in the field of nanomedicines, bioconjugation chemistry and molecular imaging. He studied chemistry at the Technical University in Berlin with completing his Ph.D. thesis in 1993 on the subject of olfactory compounds studying odor-structure relationships. From 1994 to 2000, he worked at the Institute of Diagnostics Research at the Freie Universität Berlin, where he pioneered the emerging field of fluorescence imaging and the design of optical imaging probes and targeted fluorescence dyes. In subsequent industrial positions at Schering AG and Bayer Schering Pharma, Kai Licha developed imaging probes towards clinical application, such as a near-infrared dye tested in Phase I trials for optical mammography.
In 2008, he (co)founded mivenion GmbH, a life-science company focusing on personalized medicine for patients with inflammatory and autoimmune diseases. Xiralite®, the first dedicated imaging device for the visualization of altered microcirculation in joints was developed to EU and US market approval. In close collaboration with Rainer Haag at Freie Universität, novel nanomedicines on the basis of anti-inflammatory polymers were developed and characterized with the help of fluorescent technologies. In 2010, Kai Licha completed his habilitation on intelligent fluorescent dyes and sensors. As (co)founder of the start-up epiios therapeutics, Kai Licha closed a substantial VC seed financing and established a pipeline of NCEs against sought-after cancer & liver disease targets, including protein-protein interaction (PPIs).
As organic chemist with entrepreneurial mindset and strong expertise from more than 10 years in pharmaceutical industry, he is interested in the translation of novel approaches of nanomedicines into clinical use, and also in the application of intelligent fluorescent reporters for clinical diagnostic imaging. More the 75 publications and several book chapters derived from his work.
Talk title: Multivalent Nanosystems to Target Inflammation